NS3694: an apoptosome inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10109069 |
| CHEMBL ID | 154696 |
| CHEBI ID | 92474 |
| SCHEMBL ID | 3961213 |
| MeSH ID | M000597498 |
| Synonym |
|---|
| BRD-K26979635-001-01-1 |
| ns3694, >=98%, powder |
| HSCI1_000148 |
| NCGC00165849-01 |
| ns3694 |
| apoptosis inhibitor ii, ns3694 |
| 4-chloro-2-[[3-(trifluoromethyl)phenyl]carbamoylamino]benzoic acid |
| 4-chloro-2-(3-(3-(trifluoromethyl)phenyl)ureido)benzoic acid |
| bdbm50137149 |
| 4-chloro-2-[3-(3-trifluoromethyl-phenyl)-ureido]-benzoic acid |
| CHEMBL154696 , |
| 426834-38-0 |
| 4-chloro-2-[3-(3-trifluoromethyl-phenyl)-ureido]benzoic acid |
| SCHEMBL3961213 |
| ns 3694 |
| DTXSID00435797 |
| CHEBI:92474 |
| gncztzcpxfdpli-uhfffaoysa-n |
| Q27164210 |
| 4-chloro-2-[[oxo-[3-(trifluoromethyl)anilino]methyl]amino]benzoic acid |
| 4-chloro-2-[3-(3-trifluoromethylphenyl)ureido]benzoic acid |
| apoptosis inhibitor ii |
| MS-25646 |
| BSA83438 |
| HY-108356 |
| CS-0028441 |
| E98648 |
| AKOS040744983 |
| Class | Description |
|---|---|
| ureas | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 50.1187 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) | IC50 (µMol) | 5.0000 | 0.0770 | 2.6442 | 5.0000 | AID282629; AID93246 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| glutamate-gated receptor activity | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| kainate selective glutamate receptor activity | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| glutamate-gated calcium ion channel activity | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| plasma membrane | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| kainate selective glutamate receptor complex | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| presynaptic membrane | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| postsynaptic density membrane | Glutamate receptor ionotropic, kainate 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID93246 | In vitro inhibitory activity against human ionotropic glutamate receptor ionotropic kainate 1 (GluR-5) expressed in HEK293 cells. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. |
| AID282629 | Antagonist activity at human homomeric GluR5 expressed in HEK293 cells assessed as inhibition of intracellular calcium concentration by FLIPR assay | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||